- Molecular Templates is pioneering a new form of oncology therapy known as engineered toxin bodies - which use bacteria plus antibodies to target and kill cancer cells.
- The company has three candidates in trials and development partnerships agreed with Takeda and Vertex Pharmaceuticals.
- A patient death in the company's potentially pivotal trial of lead candidate MT-3724 - targeting DLBCL - has caused the FDA to put a partial clinical hold on the trial.
- Shares dropped from $11 to $8.5 on the news but are now trading at $10.3.
- Despite the lower share price, I'm not sure Molecular's shares offer value owing to safety concerns and early stage nature of the treatment - more preclinical research may be needed.
For further details see:
Molecular Templates: Progress Stalled As Partial Hold Placed On Pivotal ETB Trial